Revium Recovery, Inc. engages in the manufacturing of beverages. The company is headquartered in New York City, New York. The company went IPO on 2001-08-22. is a pre-clinical stage biopharmaceutical company. The company develops technologies and drug-delivery technological platforms. Its pipeline encompasses antibiotics for antimicrobial-resistant bacteria, immune checkpoint inhibitor adjuvant for solid tumors, and an immunization platform. The Company, through its subsidiary, LipoVation Ltd., develops a portfolio of NLP-based pharmaceutical candidates and plans to complete the development and commercialization of a series of medical technologies including: Nanoparticles-based formulation of a potent antibiotic which, based on in vitro and in vivo animal models studies, shows promising potential in combating severe life-threatening antibiotic-resistant bacteria (Nano-Mupirocin); Novel adjuvant to cancer therapies: a nanoparticles-based formulation of angiotensin receptor blockers for intravenous administration (Nano-Candesartan), and Liposomal Protein-Loaded Technology - an approach in immunization through nano particle-based vaccines.
Follow-Up Questions
What is the price performance of RVRC stock?
The current price of RVRC is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Revium Rx?
Revium Rx belongs to N/A industry and the sector is N/A
